胃癌新辅助治疗靶点的研究进展和发展方向OA北大核心CSTPCD

As an important component of gastric cancer treatment,neoadjuvant therapy has been increasingly proven to be effective and safe in reducing tumor size,improving surgical resection rates,and enhancing patient survival through clinical research data represented by the RESOLVE study.The in-depth study of targets such as human epidermal growth factor receptor-2(HER2),vascular endothelial growth factor receptor(VEGF)and its receptor(VEGFR),FGFR2,Claudin 18.2,and programmed death receptor-1(PD-1)and its ligand(PD-L1)has brought new treatment options for patients.In particular,HER2-targeted drugs and immune checkpoint inhibitors have shown encouraging efficacy in clinical trials,bringing hope for improving patient survival and prognosis.However,this field still faces many challenges,including validation of therapeutic efficacy and safety,screening of biomarkers,optimization of multi-target combination strategies,and development of treatment response evaluation criteria.In the future,neoadjuvant therapy for gastric cancer will emphasize the importance of multidisciplinary cooperation,pay more attention to individualization and precision,optimize treatment plans,and further improve treatment effectiveness and patient quality of life.